Hepatitis C News

BOSTON — In this video, John W. Ward, MD, discusses multiple presentations at The Liver Meeting that focused on testing and treatment for hepatitis C virus infection.

BOSTON — In this video, John W. Ward, MD, spoke with Healio about two presentations from The Liver Meeting that highlighted ways to overcome health disparities among patients with hepatitis C virus infection.

BOSTON — Treatment of hepatitis C virus infection in low- and middle-income countries is key to global elimination efforts, according to an abstract presented at The Liver Meeting.

BOSTON — Patients with hepatitis C virus-related cirrhosis who achieve sustained virologic response remain at risk for cancer, as well as other non-liver-related events such as diabetes, according to an abstract presented at The Liver Meeting.

BOSTON — Researchers found “significant gaps” in follow-up testing and treatment among a cohort of pregnant individuals in Canada with a diagnosis of hepatitis C virus infection, according to data presented at The Liver Meeting.

BOSTON — A treatment trial that recruited individuals chronically infected with hepatitis C virus and provided no-cost medical care helped reduce the proportion of viremic individuals in a rural Appalachian county, data showed.

BOSTON — Treatment with sofosbuvir-based direct-acting antivirals demonstrated durable sustained virologic response up to 5 years among pediatric patients with hepatitis C virus, according to findings presented at The Liver Meeting.

BOSTON — In the absence of cirrhosis, no specific precautions are needed for patients with SARS-CoV-2 infection and a history of hepatitis C virus, according to findings presented at The Liver Meeting.

BOSTON — After 12 weeks of treatment with sofosbuvir/velpatasvir in combination with tenofovir alafenamide, patients with hepatitis C virus and hepatitis B virus co-infection demonstrated high rates of sustained virologic response.

BOSTON — Direct-acting antiviral therapy for hepatitis C virus-related hepatocellular carcinoma significantly improves overall survival, but only one in four patients receive therapy, even with insurance, according to a researcher.